#USA #San Diego #biotechnology #ThinkCyte #VisionCyte

ThinkCyte Introduces VisionCyte for Drug Discovery and Disease Research

ThinkCyte, a pioneering biotechnology firm from Japan, has announced the pre-commercial launch of its cutting-edge cell analysis platform, VisionCyte™, during the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, California. This significant development marks an important step in the company’s trajectory to revolutionize drug discovery and disease research with advanced artificial intelligence (AI) technologies.

Advancements with VisionCyte

The VisionCyte platform is poised to enhance life science research by leveraging high-resolution morphological profiling, state-of-the-art high-throughput capabilities, and sophisticated AI analytics. This innovative approach allows for the identification of novel biomarkers, crucial in discovering new drug targets. By integrating such technologies, VisionCyte aims to provide vital insights that could lead to pioneering therapies and diagnostics.

As ThinkCyte showcases VisionCyte at the SLAS 2025, the platform has already garnered attention by being named a finalist for the New Product Award, highlighting its potential impact in the field. The full commercial rollout is planned for later in 2025, with initial customer-ready units expected to be available in the second half of the year.

Expansion of Product Line

The introduction of VisionCyte expands ThinkCyte's already impressive portfolio, which began with its flagship product, VisionSort, launched in 2023. VisionSort has been widely adopted by leading biopharmaceutical companies and research institutions around the globe, demonstrating the need for innovative solutions in scientific research.

In conjunction with VisionCyte, ThinkCyte also announced the launch of its Celluminate cell tracking kits. These kits are designed to complement both VisionSort and VisionCyte, enabling discovery applications in fields where current cell surface markers are limited, such as specific hematological conditions, stem cell research, and the study of age-related diseases.

Commitment to Advancing Research

Waichiro Katsuda, CEO of ThinkCyte, emphasized the company’s dedication to advancing life science research: "The expansion of our product portfolio reflects our unwavering commitment to advancing life science research. By introducing innovative solutions that address the evolving needs of scientists worldwide, we’re not just adding products - we’re providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives."

Looking Ahead

As ThinkCyte prepares for the full commercial launch, the scientific community eagerly anticipates the capabilities that VisionCyte will bring to drug discovery and disease research. The company invites interested parties to learn more about the platform by visiting their booth at the SLAS conference or by checking their website at thinkcyte.com/visioncyte.

Founded in 2016 with offices in Tokyo, Japan, and Redwood City, California, ThinkCyte develops innovative scientific instruments based on integrated, multidisciplinary technologies. Its proprietary Ghost Cytometry™ technology offers a label-free method for cell analysis and sorting, which has significant implications for research and therapeutic development. The company's partnership with major global biopharmaceutical companies and leading academic research institutions positions it at the forefront of the biotechnology field.

For more details on ThinkCyte’s current endeavors and future projects, check their official website.